Abstract

Objectives: The purpose of this study was to review our experience with tipstein‐Barr virus (EBV) hepatitis after liver transplantation. Methods: During a 68–month period, we performed 668 liver transplants and 585 patients. We identifled 11 patients (2 percent), including 5 adults and 6 children with EBV hepatitis after liver transplantation. The diagnosis of EBV hepatitis was established by evaluating allograft biopsies. the histology was confirmed by the use of polymerase chain reaction technology. Results: The average time of diagnosis after liver transplantation was 45 days. Eight of eleven cases occurred within the first six months after transplantation. After the diagnosis of EBV hepatitis, treatment consisted of a decrease in immunosuppression plus antiviral therapy and intravenous immunoglobulin. The one‐year actuarial survival for patients with EBV hepatitis, was 73 percent (8 of 11). Two patients died of progressive multi‐organ EBV involvement. To determine the risk of developing EBV hepatitis, we reviewed our experience with the administration of antilympho‐cyte preparations in 585 patients. the patients found to have a significantly greater risk of developing EBV hepatitis included those receiving more than one course of antilymphocyte therapy or greater than a total dose of 70 milligrams of OKT3 in a single course. Conclusions: EBV hepatitis after liver transplantation is an infrequent event, which may be treated successfully. The occurrence of EBV hepatitis appears closely linked to the use of antilymphocyte preparations.

Original languageEnglish (US)
Pages (from-to)1066-1070
Number of pages5
JournalThe American journal of gastroenterology
Volume89
Issue number7
DOIs
StatePublished - Jul 1994

Fingerprint

Hepatitis Viruses
Human Herpesvirus 4
Liver Transplantation
Hepatitis
Muromonab-CD3
Intravenous Immunoglobulins
Immunosuppression
Antiviral Agents
Allografts
Histology
Therapeutics
Transplantation
Technology
Transplants
Biopsy
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Epstein‐Barr Virus Hepatitis after Liver Transplantation. / Langnas, Alan Norman; Markin, Rodney Smith; Inagaki, M.; Stratta, R. J.; Sorrell, Michael Floyd; Donovan, J. P.; Shaw, B. W.

In: The American journal of gastroenterology, Vol. 89, No. 7, 07.1994, p. 1066-1070.

Research output: Contribution to journalArticle

@article{377d47b9dc3042a3ba7d97cd1ec26194,
title = "Epstein‐Barr Virus Hepatitis after Liver Transplantation",
abstract = "Objectives: The purpose of this study was to review our experience with tipstein‐Barr virus (EBV) hepatitis after liver transplantation. Methods: During a 68–month period, we performed 668 liver transplants and 585 patients. We identifled 11 patients (2 percent), including 5 adults and 6 children with EBV hepatitis after liver transplantation. The diagnosis of EBV hepatitis was established by evaluating allograft biopsies. the histology was confirmed by the use of polymerase chain reaction technology. Results: The average time of diagnosis after liver transplantation was 45 days. Eight of eleven cases occurred within the first six months after transplantation. After the diagnosis of EBV hepatitis, treatment consisted of a decrease in immunosuppression plus antiviral therapy and intravenous immunoglobulin. The one‐year actuarial survival for patients with EBV hepatitis, was 73 percent (8 of 11). Two patients died of progressive multi‐organ EBV involvement. To determine the risk of developing EBV hepatitis, we reviewed our experience with the administration of antilympho‐cyte preparations in 585 patients. the patients found to have a significantly greater risk of developing EBV hepatitis included those receiving more than one course of antilymphocyte therapy or greater than a total dose of 70 milligrams of OKT3 in a single course. Conclusions: EBV hepatitis after liver transplantation is an infrequent event, which may be treated successfully. The occurrence of EBV hepatitis appears closely linked to the use of antilymphocyte preparations.",
author = "Langnas, {Alan Norman} and Markin, {Rodney Smith} and M. Inagaki and Stratta, {R. J.} and Sorrell, {Michael Floyd} and Donovan, {J. P.} and Shaw, {B. W.}",
year = "1994",
month = "7",
doi = "10.1111/j.1572-0241.1994.tb03225.x",
language = "English (US)",
volume = "89",
pages = "1066--1070",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Epstein‐Barr Virus Hepatitis after Liver Transplantation

AU - Langnas, Alan Norman

AU - Markin, Rodney Smith

AU - Inagaki, M.

AU - Stratta, R. J.

AU - Sorrell, Michael Floyd

AU - Donovan, J. P.

AU - Shaw, B. W.

PY - 1994/7

Y1 - 1994/7

N2 - Objectives: The purpose of this study was to review our experience with tipstein‐Barr virus (EBV) hepatitis after liver transplantation. Methods: During a 68–month period, we performed 668 liver transplants and 585 patients. We identifled 11 patients (2 percent), including 5 adults and 6 children with EBV hepatitis after liver transplantation. The diagnosis of EBV hepatitis was established by evaluating allograft biopsies. the histology was confirmed by the use of polymerase chain reaction technology. Results: The average time of diagnosis after liver transplantation was 45 days. Eight of eleven cases occurred within the first six months after transplantation. After the diagnosis of EBV hepatitis, treatment consisted of a decrease in immunosuppression plus antiviral therapy and intravenous immunoglobulin. The one‐year actuarial survival for patients with EBV hepatitis, was 73 percent (8 of 11). Two patients died of progressive multi‐organ EBV involvement. To determine the risk of developing EBV hepatitis, we reviewed our experience with the administration of antilympho‐cyte preparations in 585 patients. the patients found to have a significantly greater risk of developing EBV hepatitis included those receiving more than one course of antilymphocyte therapy or greater than a total dose of 70 milligrams of OKT3 in a single course. Conclusions: EBV hepatitis after liver transplantation is an infrequent event, which may be treated successfully. The occurrence of EBV hepatitis appears closely linked to the use of antilymphocyte preparations.

AB - Objectives: The purpose of this study was to review our experience with tipstein‐Barr virus (EBV) hepatitis after liver transplantation. Methods: During a 68–month period, we performed 668 liver transplants and 585 patients. We identifled 11 patients (2 percent), including 5 adults and 6 children with EBV hepatitis after liver transplantation. The diagnosis of EBV hepatitis was established by evaluating allograft biopsies. the histology was confirmed by the use of polymerase chain reaction technology. Results: The average time of diagnosis after liver transplantation was 45 days. Eight of eleven cases occurred within the first six months after transplantation. After the diagnosis of EBV hepatitis, treatment consisted of a decrease in immunosuppression plus antiviral therapy and intravenous immunoglobulin. The one‐year actuarial survival for patients with EBV hepatitis, was 73 percent (8 of 11). Two patients died of progressive multi‐organ EBV involvement. To determine the risk of developing EBV hepatitis, we reviewed our experience with the administration of antilympho‐cyte preparations in 585 patients. the patients found to have a significantly greater risk of developing EBV hepatitis included those receiving more than one course of antilymphocyte therapy or greater than a total dose of 70 milligrams of OKT3 in a single course. Conclusions: EBV hepatitis after liver transplantation is an infrequent event, which may be treated successfully. The occurrence of EBV hepatitis appears closely linked to the use of antilymphocyte preparations.

UR - http://www.scopus.com/inward/record.url?scp=0028275278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028275278&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1994.tb03225.x

DO - 10.1111/j.1572-0241.1994.tb03225.x

M3 - Article

C2 - 8017367

AN - SCOPUS:0028275278

VL - 89

SP - 1066

EP - 1070

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 7

ER -